Recently, the pathophysiological role of PPAR-γ was reported in the inflammatory immune response and identified as a major drug target for the treatment of psoriasis, benign epidermal tumors, and atopic dermatitis (Sertznig and Reichrath, 2011). This evidence concerns the gene PPARG and psoriasis.